

Andrew G Renehan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6757355/publications.pdf>

Version: 2024-02-01

177
papers

17,971
citations

30070

54
h-index

13379

130
g-index

186
all docs

186
docs citations

186
times ranked

23602
citing authors

#	ARTICLE	IF	CITATIONS
1	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. <i>BMC Medicine</i> , 2022, 20, 59.	5.5	3
2	Clinico-pathological predictors of clinical complete response in rectal cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100540.	1.7	10
3	Link Between Obesity and Early-Onset Colorectal Cancers (EOCRC): Importance of Accounting for BMI Trajectories in Early Life. <i>American Journal of Gastroenterology</i> , 2022, 117, 812-812.	0.4	2
4	Weight Changes in Type 2 Diabetes and Cancer Risk: A Latent Class Trajectory Model Study. <i>Obesity Facts</i> , 2022, 15, 150-159.	3.4	1
5	Body mass index and cancer mortality in patients with incident type 2 diabetes: A population-based study of adults in England. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 620-630.	4.4	3
6	Cancer survivorship, excess body fatness and weight-loss intervention—where are we in 2020?. <i>British Journal of Cancer</i> , 2021, 124, 1057-1065.	6.4	29
7	Cancer prevention through weight control—where are we in 2020?. <i>British Journal of Cancer</i> , 2021, 124, 1049-1056.	6.4	12
8	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 43-50.	10.7	122
9	Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer. <i>BMC Cancer</i> , 2021, 21, 502.	2.6	2
10	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
11	Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. <i>Surgical Oncology</i> , 2021, 38, 101572.	1.6	5
12	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Annals of Oncology</i> , 2021, 32, 1087-1100.	1.2	100
13	Watch and wait or surgery for clinical complete response in rectal cancer: a need to study both sides. <i>Colorectal Disease</i> , 2020, 22, 839-840.	1.4	4
14	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study. <i>BMJ Open</i> , 2020, 10, e027630.	1.9	6
15	Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study. <i>BMC Cancer</i> , 2020, 20, 1165.	2.6	1
16	Cancer and cardiovascular disease. <i>Lancet</i> , The, 2020, 395, 1903-1904.	13.7	6
17	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>BMJ</i> , 2020, 370, n1111.	6.4	21
18	Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence. <i>Clinical Oncology</i> , 2020, 32, 591-608.	1.4	33

#	ARTICLE	IF	CITATIONS
19	Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990–2014). <i>British Journal of Cancer</i> , 2020, 122, 749-758.	6.4	7
20	Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). <i>European Journal of Surgical Oncology</i> , 2019, 45, 2310-2315.	1.0	13
21	Interaction between co-morbidities and cancer survival. <i>European Journal of Epidemiology</i> , 2019, 34, 1103-1105.	5.7	7
22	Top ten research priorities for detecting cancer early. <i>Lancet Public Health</i> , The, 2019, 4, e551.	10.0	45
23	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019, 21, 387-391.	1.4	14
24	Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. <i>European Journal of Cancer</i> , 2019, 117, 48-59.	2.8	5
25	Awareness of the link between obesity and cancer in UK school curricula. <i>Lancet</i> , The, 2019, 393, 1591-1592.	13.7	4
26	Cancer surveillance, obesity, and potential bias. <i>Lancet Public Health</i> , The, 2019, 4, e218.	10.0	0
27	COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. <i>PLoS Medicine</i> , 2019, 16, e1002742.	8.4	284
28	Watch-and-wait strategy in rectal cancer – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 97.	8.1	1
29	Linkage of the UK Clinical Practice Research Datalink with the national cancer registry. <i>European Journal of Epidemiology</i> , 2019, 34, 101-102.	5.7	3
30	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019, 144, 641-650.	5.1	87
31	Development of MR quantified pancreatic fat deposition as a cancer risk biomarker. <i>Pancreatology</i> , 2018, 18, 429-437.	1.1	11
32	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). <i>Colorectal Disease</i> , 2018, 20, 371-382.	1.4	20
33	Prognostic relevance and performance characteristics of serum IGF1 and PAPP-A in women with breast cancer: a long-term Danish cohort study. <i>Cancer Medicine</i> , 2018, 7, 2391-2404.	2.8	13
34	A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 865-873.	8.1	51
35	Is 'watch-and-wait' after chemoradiotherapy safe in patients with rectal cancer?. <i>BMJ: British Medical Journal</i> , 2018, 363, k4472.	2.3	15
36	Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 825-836.	8.1	125

#	ARTICLE	IF	CITATIONS
37	Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2095.	7.4	159
38	Change in weight status from childhood to early adulthood and late adulthood risk of colon cancer in men: a population-based cohort study. <i>International Journal of Obesity</i> , 2018, 42, 1797-1803.	3.4	15
39	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. <i>Lancet, The</i> , 2018, 391, 2537-2545.	13.7	677
40	Limitations of the National Cancer Data Base to Evaluate Early-Stage Anal Cancer Treatment Outcomes. <i>JAMA Surgery</i> , 2018, 153, 691.	4.3	7
41	Framework to construct and interpret latent class trajectory modelling. <i>BMJ Open</i> , 2018, 8, e020683.	1.9	149
42	Body-mass index and metastatic melanoma outcomes. <i>Lancet Oncology, The</i> , 2018, 19, e225.	10.7	4
43	Excess Weight as a Risk Factor Common to Many Cancer Sites: Words of Caution when Interpreting Meta-analytic Evidence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 663-665.	2.5	14
44	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer—Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 976-976.	2.5	0
45	Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000369.	2.8	21
46	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	5.5	53
47	Anal cancer: different epidemiological and clinical definitions. <i>International Journal of Epidemiology</i> , 2017, 46, 2091-2092.	1.9	1
48	Childhood body mass index and height in relation to site-specific risks of colorectal cancers in adult life. <i>European Journal of Epidemiology</i> , 2017, 32, 1097-1106.	5.7	36
49	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Multidisciplinary Management. <i>Colorectal Disease</i> , 2017, 19, 37-66.	1.4	77
50	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Anal Cancer. <i>Colorectal Disease</i> , 2017, 19, 82-97.	1.4	45
51	Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. <i>Lancet Oncology, The</i> , 2017, 18, 1348-1359.	10.7	51
52	Watch-and-wait approach for rectal cancer: concepts of a subject-specific method. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 627.	8.1	4
53	Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. <i>BMJ Open</i> , 2017, 7, e018726.	1.9	24
54	Obesity as an Avoidable Cause of Cancer (Attributable Risks). <i>Recent Results in Cancer Research</i> , 2016, 208, 243-256.	1.8	20

#	ARTICLE	IF	CITATIONS
55	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4284-4294.	1.6	45
56	Watch-and-wait versus surgical resection for patients with rectal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e134-e135.	10.7	7
57	Collider Bias Is Only a Partial Explanation for the Obesity Paradox. <i>Epidemiology</i> , 2016, 27, 525-530.	2.7	98
58	The Obesity Paradox in Cancer: a Review. <i>Current Oncology Reports</i> , 2016, 18, 56.	4.0	386
59	Obesity and endometrial cancer: unanswered epidemiological questions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 175-178.	2.3	13
60	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. <i>British Journal of Cancer</i> , 2016, 114, 281-289.	6.4	75
61	Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer. <i>Clinical Oncology</i> , 2016, 28, 103-115.	1.4	10
62	Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. <i>Lancet Oncology</i> , The, 2016, 17, 174-183.	10.7	592
63	A framework for the <i>in vitro</i> evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. <i>Carcinogenesis</i> , 2015, 36, 1040-1050.	2.8	15
64	Obesity and cancer: links with survival differ from those with incidence. <i>Annals of Oncology</i> , 2015, 26, 821.	1.2	1
65	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 115-122.e2.	2.3	43
66	Adiposity and cancer risk: new mechanistic insights from epidemiology. <i>Nature Reviews Cancer</i> , 2015, 15, 484-498.	28.4	467
67	Digital histology quantification of intra-hepatic fat in patients undergoing liver resection. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1020-1027.	1.0	8
68	Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis. <i>Cancer Causes and Control</i> , 2015, 26, 859-870.	1.8	9
69	A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. <i>Lancet</i> , The, 2015, 385, S90.	13.7	23
70	High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. <i>European Journal of Cancer</i> , 2015, 51, 776-785.	2.8	74
71	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> , 2015, 58, 493-504.	6.3	140
72	Global burden of cancer attributable to high body-mass index in 2012: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 36-46.	10.7	718

#	ARTICLE	IF	CITATIONS
73	Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. <i>European Journal of Cancer</i> , 2015, 51, 1164-1187.	2.8	403
74	Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014, 114, E70-E73.	2.5	30
75	Comment on Bordeleau et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014, 37, e221-e222.	8.6	4
76	Re: Prediagnosis Body Mass Index, Physical Activity, and Mortality in Endometrial Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt375-djt375.	6.3	8
77	Chronic Insulin Exposure does not Cause Insulin Resistance but is Associated with Chemo-resistance in Colon Cancer Cells. <i>Hormone and Metabolic Research</i> , 2014, 46, 85-93.	1.5	13
78	Impact of mechanical bowel preparation on survival after colonic cancer resection (<i>Br J Surg</i> 2014;): Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.3	2
79	Excess adiposity and gastrointestinal cancer. <i>British Journal of Surgery</i> , 2014, 101, 1518-1531.	0.3	26
80	Excess adiposity and survival in patients with colorectal cancer: a systematic review. <i>Obesity Reviews</i> , 2014, 15, 434-451.	6.5	56
81	Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1436-1444.	1.0	17
82	Diabetes and cancer: 5 years into the recent controversy. <i>European Journal of Cancer</i> , 2014, 50, 2119-2125.	2.8	46
83	Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 341-345.	2.4	28
84	Slowing down of adult body mass index trend increases in England: a latent class analysis of cross-sectional surveys (1992-2010). <i>International Journal of Obesity</i> , 2014, 38, 818-824.	3.4	66
85	The impact of excess body weight at the hospital frontline. <i>BMC Medicine</i> , 2014, 12, 64.	5.5	3
86	Abstract LB-276: Prospective study of body mass index and adult weight change with colorectal cancer survival, overall and by tumor microsatellite instability status. , 2014, , .		0
87	The interaction between prognostic and pharmacodynamic biomarkers. <i>British Journal of Cancer</i> , 2013, 109, 1782-1785.	6.4	0
88	Comparison of Associations of Body Mass Index, Abdominal Adiposity, and Risk of Colorectal Cancer in a Large Prospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1383-1394.	2.5	50
89	The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. <i>Hpb</i> , 2013, 15, 463-472.	0.3	23
90	Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. <i>Diabetes Care</i> 2011;34:1965-1971. <i>Diabetes Care</i> , 2012, 35, e15-e15.	8.6	3

#	ARTICLE	IF	CITATIONS
91	Body Mass Index at Different Adult Ages, Weight Change, and Colorectal Cancer Risk in the National Institutes of Health-AARP Cohort. <i>American Journal of Epidemiology</i> , 2012, 176, 1130-1140.	3.4	77
92	Cumulative incidence of metachronous colorectal cancer risk for mismatch repair gene mutation carriers is overestimated: Figure 1. <i>Gut</i> , 2012, 61, 783.1-783.	12.1	4
93	Growth Hormone Receptor Polymorphism and Growth Hormone Therapy Response in Children: A Bayesian Meta-Analysis. <i>American Journal of Epidemiology</i> , 2012, 175, 867-877.	3.4	33
94	Re: Body Mass Index and Risk of Lung Cancer Among Never, Former, and Current Smokers. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1680-1681.	6.3	16
95	Utility of 18â€fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer. <i>ANZ Journal of Surgery</i> , 2012, 82, 729-736.	0.7	5
96	Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial. <i>European Journal of Cancer</i> , 2012, 48, 853-864.	2.8	77
97	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1518-1524.	6.4	33
98	Current Treatment of Anal Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1315-1350.	2.2	20
99	Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. <i>British Journal of Surgery</i> , 2012, 99, 987-992.	0.3	84
100	Body composition and outcome in patients undergoing resection of colorectal liver metastases (<i>Br J Surg</i> 2012; 99: 550â€557). <i>British Journal of Surgery</i> , 2012, 99, 1021-1022.	0.3	13
101	Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. <i>Diabetologia</i> , 2012, 55, 1607-1618.	6.3	191
102	Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. <i>Diabetologia</i> , 2012, 55, 1619-1632.	6.3	109
103	Insulin analogues and cancer risk: the emergence of second-generation studies. <i>Diabetologia</i> , 2012, 55, 7-9.	6.3	31
104	Height and cancer: consistent links, but mechanisms unclear. <i>Lancet Oncology</i> , The, 2011, 12, 716-717.	10.7	25
105	Initial management through the anal cancer multidisciplinary team meeting. <i>Colorectal Disease</i> , 2011, 13, 21-28.	1.4	15
106	Management of Local Disease Relapse. <i>Colorectal Disease</i> , 2011, 13, 44-52.	1.4	23
107	The development of composite circulating biomarker models for use in anticancer drug clinical development. <i>International Journal of Cancer</i> , 2011, 128, 1843-1851.	5.1	7
108	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2912-2920.	3.6	131

#	ARTICLE	IF	CITATIONS
109	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. <i>Nature Reviews Endocrinology</i> , 2011, 7, 11-24.	9.6	300
110	The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper. <i>Cancers</i> , 2011, 3, 2302-2315.	3.7	8
111	Incident cancer burden attributable to excess body mass index in 30 European countries. <i>International Journal of Cancer</i> , 2010, 126, 692-702.	5.1	227
112	Colorectal Cancer Incidence Trends in the United States and United Kingdom: Evidence of Right- to Left-Sided Biological Gradients with Implications for Screening. <i>Cancer Research</i> , 2010, 70, 5419-5429.	0.9	105
113	Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3119-3130.	2.5	231
114	Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. <i>Gut</i> , 2010, 59, 289-290.	12.1	7
115	The long road towards cancer prevention: 4 steps backward and 8 forward. <i>European Journal of Cancer</i> , 2010, 46, 2660-2662.	2.8	11
116	Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction. <i>European Journal of Cancer</i> , 2010, 46, 2605-2616.	2.8	51
117	Foreword: Implementing cancer prevention in Europe. <i>European Journal of Cancer</i> , 2010, 46, 2523-2524.	2.8	7
118	Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. <i>European Journal of Cancer</i> , 2010, 46, 2581-2592.	2.8	86
119	Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives. <i>Annual Review of Medicine</i> , 2010, 61, 301-316.	12.2	541
120	Linking diabetes and cancer: a consensus on complexity. <i>Lancet, The</i> , 2010, 375, 2201-2202.	13.7	81
121	Obesity and cancer in Asia-Pacific populations. <i>Lancet Oncology, The</i> , 2010, 11, 704-705.	10.7	4
122	Physical Activity Before and After Diagnosis of Colorectal Cancer. , 2010, , 153-172.		0
123	Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. <i>Colorectal Disease</i> , 2009, 11, 547-563.	1.4	165
124	Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. <i>Colorectal Disease</i> , 2009, 11, 689-701.	1.4	177
125	Bariatric surgery, weight reduction, and cancer prevention. <i>Lancet Oncology, The</i> , 2009, 10, 640-641.	10.7	56
126	Treatments and Outcomes of Peritoneal Surface Tumors Through a Centralized National Service (United Kingdom). <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1705-1714.	1.3	30

#	ARTICLE	IF	CITATIONS
127	Systematic reviews and meta-analyses in coloproctology: interpretation and potential pitfalls. <i>Colorectal Disease</i> , 2008, 10, 21-32.	1.4	15
128	Reciprocal relationship between expression of hypoxia inducible factor 1 \pm (HIF-1 \pm) and the pro-apoptotic protein Bid in ex vivo colorectal cancer. <i>British Journal of Cancer</i> , 2008, 99, 459-463.	6.4	11
129	A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2008, 99, 591-596.	6.4	91
130	Acromegaly, growth hormone and cancer risk. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 639-657.	4.7	83
131	Obesity and cancer: Pathophysiological and biological mechanisms. <i>Archives of Physiology and Biochemistry</i> , 2008, 114, 71-83.	2.1	352
132	Meta-analysis in medical research: Potentials and limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 320-329.	1.6	53
133	Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. <i>Lancet</i> , The, 2008, 371, 569-578.	13.7	4,292
134	Insulin and Cancer: Report of the Proceedings of the First International Workshop, October 27-28, 2007, D $\frac{1}{4}$ sseldorf, Germany. <i>Pediatric Endocrinology Reviews</i> , 2008, 5, 810-6.	1.2	2
135	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007, 17, 210-219.	1.1	6
136	Physical Activity Before and After Diagnosis of Colorectal Cancer. <i>Sports Medicine</i> , 2007, 37, 947-960.	6.5	40
137	Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. <i>Colorectal Disease</i> , 2007, 9, 393-396.	1.4	1
138	Obesity and cancer risk: the role of the insulin-IGF axis. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 328-336.	7.1	418
139	Towards a more prescriptive follow-up regimen for colorectal cancer. <i>Colorectal Disease</i> , 2006, 8, 623-625.	1.4	4
140	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006, 13, 273-278.	3.1	115
141	A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2006, 95, 1258-1264.	6.4	42
142	Systematic reviews: challenging dogmas and uncovering potential harms. <i>Colorectal Disease</i> , 2005, 7, 1-3.	1.4	7
143	Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. <i>Clinical Endocrinology</i> , 2005, 62, 323-330.	2.4	21
144	IGF-I, IGF binding protein-3 and breast cancer risk: Comparison of 3 meta-analyses. <i>International Journal of Cancer</i> , 2005, 115, 1006-1007.	5.1	35

#	ARTICLE	IF	CITATIONS
145	Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. <i>British Journal of Surgery</i> , 2005, 92, 605-614.	0.3	149
146	Insulin-Like Growth Factor-Binding Protein-3, Breast Cancer Risk, and Different Serum Assays. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1844-1844.	2.5	4
147	Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. <i>British Journal of Cancer</i> , 2005, 92, 430-433.	6.4	54
148	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005, 365, 1449-1451.	13.7	36
149	The effect of cigarette smoking use and cessation on serum insulin-like growth factors. <i>British Journal of Cancer</i> , 2004, 91, 1525-1531.	6.4	29
150	Systematic review, Cochrane and Colorectal Disease. <i>Colorectal Disease</i> , 2004, 6, 73-74.	1.4	4
151	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. <i>Lancet, The</i> , 2004, 363, 1346-1353.	13.7	1,536
152	Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise. <i>British Journal of Cancer</i> , 2003, 89, 1610-1613.	6.4	209
153	Re: Sternomastoid flap after superficial parotidectomy. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2003, 41, 281.	0.8	0
154	Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. <i>Growth Hormone and IGF Research</i> , 2003, 13, 341-346.	1.1	28
155	Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. <i>Gut</i> , 2003, 52, 1071-a-1072.	12.1	7
156	Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications. <i>Hormone and Metabolic Research</i> , 2003, 35, 712-725.	1.5	101
157	Gender and age influence the relationship between serum GH and IGF-1 in patients with acromegaly. <i>Clinical Endocrinology</i> , 2002, 57, 59-64.	2.4	39
158	High-risk colorectal adenomas and serum insulin-like growth factors. <i>British Journal of Surgery</i> , 2002, 88, 107-113.	0.3	71
159	Early cellular events in colorectal carcinogenesis. <i>Colorectal Disease</i> , 2002, 4, 76-89.	1.4	53
160	Acromegaly and Colorectal Cancer: Risk Assessment Should Be Based on Population-Based Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1909-1909.	3.6	13
161	Screening colonoscopy for acromegaly in perspective*. <i>Clinical Endocrinology</i> , 2001, 55, 731-733.	2.4	29
162	Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. <i>Clinical Endocrinology</i> , 2001, 55, 469-475.	2.4	10

#	ARTICLE	IF	CITATIONS
163	What is apoptosis, and why is it important?. BMJ: British Medical Journal, 2001, 322, 1536-1538.	2.3	205
164	Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis, 2000, 21, 469-476.	2.8	288
165	Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated Reply. Gut, 2000, 46, 440-440.	12.1	14
166	Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. British Journal of Cancer, 2000, 83, 1344-1350.	6.4	101
167	Surveillance after colorectal cancer resection. Lancet, The, 2000, 355, 1095-1096.	13.7	7
168	Circulating Insulin-Like Growth Factor II and Colorectal Adenomas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3402-3408.	3.6	55
169	The Prevalence and Characteristics of Colorectal Neoplasia in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3417-3424.	3.6	33
170	Re: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. Journal of the National Cancer Institute, 1999, 91, 2051-2052.	6.3	6
171	Clinico-pathological and treatment-related factors influencing survival in parotid cancer. British Journal of Cancer, 1999, 80, 1296-1300.	6.4	142
172	Clinico-pathological and treatment-related factors influencing survival in parotid cancer. British Journal of Cancer, 1999, 80, 1296-1300.	6.4	30
173	A selective policy in follow-up for bowel cancer. Lancet, The, 1998, 351, 1891.	13.7	0
174	An analysis of the treatment of 114 patients with recurrent pleomorphic adenomas of the parotid gland. American Journal of Surgery, 1996, 172, 710-714.	1.8	111
175	FDG PET-CT imaging for pre operative staging in patients with colorectal cancer. The Cochrane Library, 0, , .	2.8	4
176	Radiotherapy versus combined modality therapy for anal carcinoma. The Cochrane Library, 0, , .	2.8	0
177	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. , 0, .		1